AbbVie-Allergan deal not eligible for fast-track review in Brazil, CADE says
MLex Summary: AbbVie’s proposed merger with Allergan can't be reviewed under the fast-track procedure, Brazilian antitrust investigators said in a decision. The Superintendence of the Administrative Council for Economic Defense, or CADE,...To view the full article, register now.
Already a subscriber? Click here to view full article